BioBreakthroughs

Join us on the latest episode! Our Guest: Dr. Helen Torley, President & CEO at Halozyme

What you'll get out of this episode:

• Introduction to Dr. Helen Torley, CEO and president of Halozyme.
• Halozyme's mission to reduce treatment burdens for patients.
• The revolutionary Enhanze technology: Transforming IV infusions to subcutaneous injections.
• The significant impact of Halozyme's innovations on healthcare systems.
• The power of partnerships in driving Halozyme's success.

To learn more about Halozyme: https://halozyme.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

#Halozyme #InnovationInHealthcare #DrugDelivery #BioBreakthroughs #PatientCare

Join us on the latest episode! Our Guest: Marisa Cruz, M.D. Chief Medical Officer at Empatica

What you'll get out of this episode:

• Exploring Dr. Cruz's background in FDA and her transition to the private sector.
• Overview of Empatica: Foundation, mission, and their cutting-edge Health Monitoring Platform.
• The value of digital biomarkers in research.
• Advancements in remote patient monitoring and its significance in decentralized clinical trials.
• How Empatica ensures data protection and patient safety during clinical trials.
• A sneak peek into what's next for Empatica: Actigraphy mode and more!
• Closing thoughts and looking forward to future discussions.

To learn more about Empatica: https://www.empatica.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

#DigitalHealth #Empatica #PatientMonitoring #ClinicalTrials #HealthTech #BioBreakthroughs

Join us on the latest episode! Our Guest: Raquel Izumi, President & COO at Vincerx Pharma Inc

What you'll get out of this episode:

• Raquel's academic background & introduction to drug development.
• The inspiration drawn from personal experiences and influential figures in the biotech industry.
• Challenges of co-founding multiple companies.
• The innovation behind Vincerx Pharma.
• The potential of antibody drug conjugates in modern medicine.
• Insights into Vincerx's upcoming ADC VIP 943.
• The vision and goals for Vincerx in the coming years.
• Key learnings Raquel has drawn from her vast experience in the biotech world.

To learn more about Vincerx Pharma Inc: https://vincerx.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

Join us on the latest episode! Our Guest: Javier Swarcberg, CEO of Spruce Biosciences

What you'll get out of this episode:

• Dive deep into the world of Congenital Adrenal Hyperplasia (CAH) treatments and drug development.
• Understand the challenges and rewards of addressing rare diseases, especially in pediatrics.
• Javier Szwarcberg discusses Spruce's innovative Tildesophon and its potential impact on the CAH therapeutic landscape.
• Discover the upcoming clinical updates from Spruce Biosciences and the promising future outlook for CH treatments.

To learn more about Spruce Biosciences: https://sprucebio.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

Join us on the latest episode! Our Guest: Paul Billings, CEO And Director Of Biological Dynamics

What you'll get out of this episode:

• Harvard MD/PhD, former physician, current CEO focusing on personalized medicine.
• Biological Dynamics Overview: 10-year-old company, isolates plasma particles from minimal blood samples for diagnostics.
• Aiming for early-stage detection of pancreatic cancer to improve survival rates.
• Their unique approach to target exosomes instead of DNA/RNA for richer data; aims to replace invasive tests.
• Expanding technology to other cancers and potentially Alzheimer's; involved in clinical trials.

To learn more about Biolgical Dynamics: https://biologicaldynamics.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

Join us on the latest episode! Our Guest: Simon Arkell, CEO and Co-Founder of Synthetica Bio

What you'll get out of this episode:

- Simon Arkell, CEO of Synthetica Bio, sheds light on biopharma's future
- Originally an Australian athlete, Arkell became a U.S.-based entrepreneur, focusing on machine learning, data analytics, and patient care.
- His standout contribution was through DeepLens in precision oncology.
- Synthetica Bio aims to provide advanced data solutions in biopharma using generative AI, addressing the industry's data analysis challenges.
- Despite abundant data, biopharma grapples with analysis bottlenecks due to task-specific traditional models.
- Synthetica Bio differentiates itself with versatile data interpretation using generative AI and a unique cloud-based microservices architecture.
- With backing from major venture capitalists and strategic partnerships, Synthetica Bio is on track for significant industry innovation.
- Overall, Synthetica Bio is driving transformation in biopharma, maximizing generative AI's potential.

To learn more about Synthetica Bio: https://syntheticabio.ai/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

Join us on the latest episode! Our Guest: Ravi Samavedam, Chief Innovation Officer At Azzur Group

What you'll get out of this episode:

- Ravi Samavedam of Azzur Group discusses lab space solutions for biotech.
- Azzur Group's clean rooms on demand address lab space shortages, offering flexible configurations.
- Their model eases GMP compliance burden by managing facilities and support services.
- Azzur Group accelerates therapies, focusing on cell and gene therapy innovation.
- Expansion plans aim to amplify their impact in the industry.

To learn more about Azzur Group: https://azzur.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

Join us on the latest episode! Our Guest: Pascal Touchon, President and CEO at Atara Biotherapeutics

What you'll get out of this episode:

- Backstory on Pascal
- Leading CAR-T at Novartis and Atara, focusing on lymphoma.
- Creation of EBV T Cell Platform for cancer and autoimmune diseases.
- The milestones for Ebalo, including European approval.
- Impacting cell therapy with validation, quality manufacturing.
- Planned future directions, including FDA alignment and partnerships.

To learn more about Atara Biotherapeutics: https://www.atarabio.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

Join us on the latest episode! Our Guest: Jason Bock, CEO At CTMC

What you'll get out of this episode:

- Jason’s path to founding CTMC
- An overview of CTMC
- CTMC’s mission
- CTMC’s unique partnership with MD Anderson
- The exciting opportunities at CTMC
- CTMC’s mission to help patients & advancing novel scientific breakthroughs into medicines to ultimately end cancer
- The future of CTMC & the industry

To learn more about CTMC+: https://ctmc.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

Join us on the latest episode! Our Guest: Pete O'Heeron, Chairman/CEO/Founder, FibroBiologics

What you'll get out of this episode:

• Pete's background
• Overview of FibroBiologics
• Their fibroblast technology platform and its therapeutic potential
• What his formula has been for growing and scaling the team and product pipeline
• Key takeaways from #BIO2023
• What trends do he sees developing right now in regenerative medicine that will continue through the end of 2023
• What's next?

To learn more about FibroBiologics: https://fibrobiologics.com/

Full Episode and more info here: https://sliceofhealthcare.com/10-pete-oheeron-chairman-ceo-founder-fibrobiologics/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/